Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4–targeting ADC) from pharmacokinetics, efficacy, and safety perspectives.
Hugh Giovinazzo, Ramil Abdrashitov, Yaogeng Wang, Garret Winkler et autres
3029 Background: B7-H4 is a transmembrane glycoprotein that is upregulated in a variety of solid tumors. BG-C9074 is an investigational topoisomerase I inhibitor antibody-drug conjugate (ADC) that targets B7-H4. We present results of the pharmacokinetic (PK) and exposure-response (ER) analyses supporting the …
ch (code pays fourni par la source)
0 citations
Journal of Clinical Oncology